Evidence map›Paper›PMID 22044226›Full record

ReviewCurrent topics in medicinal chemistry2011

Amphipathic properties of HIV-1 gp41 fusion inhibitors.

Miriam Gochin, Guangyan Zhou

Abstract readReview
In one paragraph

Review in Current topics in medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Enhanced potency of bivalent small molecule gp41 inhibitors.Bioorganic & medicinal chemistry · 2017
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Miriam GochinDepartment of Basic Sciences, Touro University – California, Vallejo, CA 94592, USA. miriam.gochin@tu.edu
Guangyan Zhou
Touro University California · US

Funding

XRAY CRYSTALLOGRAPHIC STRUCTURE ANALYSIS: PROTEIN SORTINGP41RR001081 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 1985 to 2011
$17.6M
Structure-based discovery and development of HIV-1 gp41 fusion inhibitorsR01GM087998 · NIGMS · TOURO UNIVERSITY OF CALIFORNIA · PI GOCHIN, MIRIAM · 2010 to 2013
$1.1M
Rational design of indole compounds as HIV fusion inhibitorsR21AI093243 · NIAID · TOURO UNIVERSITY OF CALIFORNIA · PI GOCHIN, MIRIAM · 2011 to 2012
$385k
Assay development for high affinity non-peptide HIV-1 gp41 inhibitorsR21NS066469 · NINDS · TOURO UNIVERSITY OF CALIFORNIA · PI GOCHIN, MIRIAM · 2009 to 2009
$145k
NCRR NIH HHS P41 RR001081NIAID NIH HHS AI093243NIAID NIH HHS R21 AI093243NIGMS NIH HHS GM087998NIGMS NIH HHS R01 GM087998NINDS NIH HHS NS066469NINDS NIH HHS R21 NS066469
6 · The paper itself

Abstract

Small molecule inhibition of HIV fusion has been an elusive goal, despite years of effort by both pharmaceutical and academic laboratories. In this review, we will discuss the amphipathic properties of both peptide and small molecule inhibitors of gp41-mediated fusion. Many of the peptides and small molecules that have been developed target a large hydrophobic pocket situated within the grooves of the coiled coil, a potential hotspot for inhibiting the trimer of hairpin formation that accompanies fusion. Peptide studies reveal molecular properties required for effective inhibition, including elongated structure and lipophilic or amphiphilic nature. The characteristics of peptides that bind in this pocket provide features that should be considered in small molecule development. Additionally, a novel site for small molecule inhibition of fusion has recently been suggested, involving residues of the loop and fusion peptide. We will review the small molecule structures that have been developed, evidence pointing to their mechanism of action and strategies towards improving their affinity. The data points to the need for a strongly amphiphilic character of the inhibitors, possibly as a means to mediate the membrane - protein interaction that occurs in gp41 in addition to the protein - protein interaction that accompanies the fusion-activating conformational transition.

Indexed as

Cell MembraneHIV-1HIV Envelope Protein gp41HIV Fusion InhibitorsHumansPeptidesVirus InternalizationHIV Envelope Protein gp41HIV Fusion InhibitorsPeptides

Identifiers

PMID22044226
PMCPMC3219813
OpenAlexW2033450817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.